Sign In
Buy PODD
$143.30
+0.87 (+0.611%)
At Close: Jun 03, 2026
Insulet (PODD) Q3 Earnings and Revenues Beat Estimates
06:52pm, Thursday, 03'rd Nov 2022
Insulet (PODD) delivered earnings and revenue surprises of 164.71% and 9.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
This insulin-pump company's stock is plunging, and executives say it's because diabetics in U.S. can't afford the technology
09:51pm, Wednesday, 02'nd Nov 2022 MarketWatch
Tandem Diabetes Care Inc. shares plummeted more than 20% after the company reported earnings Wednesday, continuing a decline that has already cost the company two-thirds of its market value this year.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
02:01pm, Monday, 31'st Oct 2022 Zacks Investment Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Insulet (PODD) to Report a Decline in Earnings: What to Look Out for
02:02pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
02:21pm, Tuesday, 18'th Oct 2022 Benzinga
Upgrades
According to Jefferies, the prior rating for Target Corp (NYSE:TGT) was changed from Hold to Buy. Target earned $0.39 in the second quarter, compared to $3.64 in the year-ago quarter. The cur
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
02:02pm, Wednesday, 12'th Oct 2022 Benzinga
Upgrades
For CME Group Inc (NASDAQ:CME), Deutsche Bank upgraded the previous rating of Hold to Buy. In the second quarter, CME Group showed an EPS of $1.97, compared to $1.64 from the year-ago quarte
Analyst Ratings for Insulet
01:24pm, Wednesday, 12'th Oct 2022 Benzinga
Over the past 3 months, 6 analysts have published their opinion on Insulet (NASDAQ:PODD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company
New Strong Sell Stocks for October 7th
11:00am, Friday, 07'th Oct 2022 Zacks Investment Research
GIII, PODD and LU have been added to the Zacks Rank #5 (Strong Sell) List on October 7, 2022.
New Strong Sell Stocks for October 7th
08:17am, Friday, 07'th Oct 2022
GIII, PODD and LU have been added to the Zacks Rank #5 (Strong Sell) List on October 7, 2022.
Insulet to Announce Third Quarter 2022 Financial Results on November 3, 2022
06:00am, Thursday, 22'nd Sep 2022
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio
05:41pm, Friday, 16'th Sep 2022 Zacks Investment Research
Investors continue to be optimistic about Insulet (PODD) on Omnipod's continued market access expansion.
3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio
03:03pm, Friday, 16'th Sep 2022
Investors continue to be optimistic about Insulet (PODD) on Omnipod's continued market access expansion.
Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up
04:08pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.
Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up
01:32pm, Tuesday, 09'th Aug 2022
Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.
Insulet Corporation (PODD) CEO Jim Hollingshead on Q2 2022 Results - Earnings Call Transcript
12:04pm, Sunday, 07'th Aug 2022
Insulet Corporation (NASDAQ:PODD ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President and
